Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder (Q34032634)

30 July 2017

Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

30 July 2017

0 references

1 reference

1 reference

ORCID Public Data File 2021

author name string

Christopher Steer

1

1 reference

30 July 2017

Jan Froelich

2

1 reference

30 July 2017

César A Soutullo

3

1 reference

30 July 2017

Mats Johnson

4

1 reference

30 July 2017

Monica Shaw

5

1 reference

30 July 2017

1 August 2012

1 reference

30 July 2017

1 reference

30 July 2017

26

1 reference

30 July 2017

8

1 reference

30 July 2017

691-705

1 reference

https://scigraph.springernature.com/pub.10.2165/11634340-000000000-00000

30 July 2017

0 references

cites work

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

The quality of life of children with attention deficit/hyperactivity disorder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

European clinical guidelines for hyperkinetic disorder -- first upgrade

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Attention-deficit disorder (attention-deficit/ hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention-deficit/hyperactivity disorder (with hyperactivity)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Lisdexamfetamine dimesylate for childhood ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, cro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

ADHD in Children Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Effect of lisdexamfetamine dimesylate on sleep in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Size of treatment effects and their importance to clinical research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

The Effect of Stimulant Treatment for ADHD on Later Substance Abuse and the Potential for Medication Misuse, Abuse, and Diversion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

The nonmedical use of prescription ADHD medications: results from a national Internet panel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Licit and illicit use of medications for Attention-Deficit Hyperactivity Disorder in undergraduate college students.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Correlates of methylphenidate use in Canadian children: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Use of medical services by methylphenidate-treated children in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

An 8-year follow-up study of profiles and predictors of methylphenidate use in a nationwide sample of boys.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Prevalence and patterns of methylphenidate use in French children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Prevalence of methylphenidate use among Israeli children: 1998-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634340-000000000-00000

Increasing trend in prescription of methylphenidate in general practices in the north-east of The Netherlands, 1998-2003

21 January 2018

1 reference

12 December 2020

Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK

1 reference

12 December 2020

Methylphenidate use for attention deficit hyperactivity disorder in northern Israel--a controversial issue.

1 reference

12 December 2020

The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.

1 reference

12 December 2020

Use of ADHD drugs in the Nordic countries: a population-based comparison study

1 reference

12 December 2020

Increased methylphenidate usage for attention deficit disorder in the 1990s

1 reference

12 December 2020

Recent trends in stimulant medication use among U.S. children

1 reference

12 December 2020

Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth

1 reference

12 December 2020

A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes

1 reference

12 December 2020

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

12 December 2020

Estimating the size of treatment effects: moving beyond p values

1 reference

12 December 2020

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

[Attention deficit hyperactivity disorder: diagnosis and drug therapy]

1 reference

12 December 2020

Anti-hyperactivity medication: methylphenidate and amphetamine

1 reference

12 December 2020

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

1 reference

12 December 2020

10.2165/11634340-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference